Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company focusing on novel therapeutics and drug delivery systems, announced a strategic initiative to explore ibogaine-based therapeutics for traumatic brain injury (TBI) and related neuropsychiatric conditions. The company has filed a provisional U.S. patent application covering compositions and methods using ibogaine and related compounds to treat TBI, post-traumatic stress disorder (PTSD), and associated disorders.
This move marks a significant expansion of Silo Pharma's pipeline, which traditionally has concentrated on stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The company's portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis.
The initiative underscores the growing interest in ibogaine, a naturally occurring psychoactive substance derived from the African shrub Tabernanthe iboga. Ibogaine has been studied for its potential to treat addiction and other neurological conditions, but its application for TBI represents a novel direction. TBI is a leading cause of disability worldwide, with limited effective pharmacological treatments. The condition often leads to long-term cognitive, behavioral, and emotional deficits, and is associated with increased risk of PTSD and other psychiatric disorders.
Silo Pharma's research is conducted in collaboration with leading universities and laboratories. The company's therapeutic focus is on addressing underserved conditions, and the ibogaine-based initiative aligns with this mission by targeting the complex pathophysiology of TBI. The provisional patent application aims to protect the company's intellectual property related to the use of ibogaine and its derivatives for TBI and related disorders.
The announcement has implications for the broader biopharmaceutical industry, as it signals a potential shift toward exploring psychedelic compounds for neurological indications beyond mental health. Ibogaine has faced regulatory hurdles due to its psychoactive properties and safety concerns, but recent research has highlighted its neuroprotective and anti-inflammatory effects, which may be beneficial in TBI.
Silo Pharma is also a cryptocurrency treasury company, but its core focus remains on developing therapeutics for conditions with high unmet needs. The company's newsroom provides updates on its progress, and more information about Silo Pharma can be found at silopharma.com.
The full press release detailing the initiative is available at https://ibn.fm/HdWHG. For investors and stakeholders, the latest news and updates relating to SILO are available in the company's newsroom at https://ibn.fm/SILO.
